Sort
4,870 grants matching “glp 1”
The Comparative Effectiveness and Safety of Second-line Therapy in Patients with Type 2 Diabetes
$150,982Jung-Im Shin · Johns Hopkins University · K01 · FY2021 · DK
The role of GLP-1 in cardiac recovery after bariatric surgery in obesity-induced heart failure
$150,874Tammy Lyn Kindel · Medical College Of Wisconsin · K08 · FY2019 · HL
The role of GLP-1 in cardiac recovery after bariatric surgery in obesity-induced heart failure
$150,874Tammy Lyn Kindel · Medical College Of Wisconsin · K08 · FY2022 · HL
The role of GLP-1 in cardiac recovery after bariatric surgery in obesity-induced heart failure
$150,874Tammy Lyn Kindel · Medical College Of Wisconsin · K08 · FY2020 · HL
The role of GLP-1 in cardiac recovery after bariatric surgery in obesity-induced heart failure
$150,874Tammy Lyn Kindel · Medical College Of Wisconsin · K08 · FY2021 · HL
Scientific Core
$150,750Tim Mosmann · University Of Rochester · U19 · FY2009 · AI
Alleviating carbohydrate counting in adults with type 1 diabetes with weekly Semaglutide injections added to an automated insulin delivery with LyumjevÂ
$150,029Michael Tsoukas · Mcgill University Health Ctr Res Inst · R01 · FY2023 · DK
Symbiotic-based discovery for a safe selective antifungal therapy
$150,000Paul G Ambrose · Symbiotica, Inc. · R43 · FY2018 · AI
Smart CSF Delivery System for CNS Drug Therapy for Leptomeningeal Disease
$150,000Marcie A Glicksman · Enclear Therapies, Inc. · R43 · FY2025 · CA
Administrative Supplement: Construction and Application of Research-Grade Cohorts from EHR for Metabolic Dysfunction-Associated Cancer Research
$149,999Suresh S Ramalingam · Emory University · P30 · FY2025 · CA
Development of Inhaled PPI for Treatment of Pulmonary Fibrosis
$149,950Ahmet S Tutuncu · Altitude Pharma, Inc. · R43 · FY2016 · HL
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF
$149,750Taneli Jouhikainen · Savara, Inc. · R43 · FY2012 · HL
A facile approach for preparing dual-agonists with long lifetimes and balanced activities
$149,575Gary W Ashley · Prolynx, Llc · R43 · FY2017 · DK
Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts
$149,295Santosh C. Sinha · Plex Pharmaceuticals, Inc. · R43 · FY2020 · EY
Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts
$149,295Sambaiah Thota · Plex Pharmaceuticals, Inc. · R43 · FY2021 · EY
Leadership Training in Real-World Data Analytics: Sleep and Alzheimer's Disease
$149,148Christopher Norfleet Kaufmann · University Of Florida · K02 · FY2025 · AG
Core C - Animal Models Core
$148,502Maria P. Limberis · University Of Pennsylvania · P01 · FY2016 · HL
Nitrite dependent protection against Cl2 gas toxicity_role of chlorinated lipids
$148,498Rakesh Pravinchandra Patel · University Of Alabama At Birmingham · U01 · FY2018 · ES
Scientific Core
$148,314Tim Mosmann · University Of Rochester · U19 · FY2010 · AI
TOTAL PARENTERAL NUTRITION AND INTESTINAL ADAPTION
$148,243University Of Wisconsin Madison · R01 · FY2000 · DK
Closing the Cardio-Renal Preventive Treatment Gap Among Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: An Implementation Science Approach
$148,186Julio Alejandro Lamprea Montealegre · University Of California, San Francisco · K99 · FY2023 · HL
Neural mechanisms controlling food intake and body weight after bariatric surgery
$148,000Hans-Rudolf Berthoud · Lsu Pennington Biomedical Research Ctr · R01 · FY2012 · DK
RISPERIDONE PHARMACOKINETICS IN CHILDREN WITH PDD
$148,000Children'S Hospital Med Ctr (Cincinnati) · R21 · FY2001 · HD
Risperidone Pharmacokinetics in Children with Pervasive*
$148,000Children'S Hospital Med Ctr (Cincinnati) · R21 · FY2002 · HD
Accumulation of Elevated Risk Associated with Treatment-Escalation Differences in patients with Type 2 Diabetes (ACCELERATED-T2D)
$147,747Kibum Kim · University Of Illinois At Chicago · K01 · FY2025 · DK